Buprenorphine is an effective medication treatment for opioid use disorder (MOUD) but access is difficult for patients, especially in rural locations. To improve access, legislation, including the Comprehensive Addiction and Recovery Act (2016) and the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act (2018), extended the ability to get a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine to treat opioid use disorder (OUD) to numerous types of clinicians. This study updates the distribution of waivered clinicians as of July 2020 and notes regional and geographic differences.
The number of DEA‐waivered clinicians more than doubled between December 2017 and July 2020 from 37,869 to 98,344. The availability of a clinician with a DEA waiver to provide MOUD has increased across all geographic categories. Nearly two‐thirds of all rural counties (63.1%) had at least one clinician with a DEA waiver but more than half of small and remote rural counties lacked one. There were also significant differences in access by the US Census Division.
Overall, MOUD access has improved, but small rural communities still experience treatment disparities and there is significant regional variation.
Contact: Holly Andrilla, MS
Authors:Andrilla CHA, Patterson DG
Journal/Publisher:Journal of Rural Health
Edition:Mar 2021. 1-6
Link to ArticleAccess the article here: Journal of Rural Health
Citation:Andrilla, CHA, Patterson, DG. Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder. J Rural Health. 2021; 1– 6. https://doi.org/10.1111/jrh.12569
Related Studies:What is the Geographic Distribution of the Workforce with a DEA Waiver to Prescribe Buprenorphine?